These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 23986307)

  • 41. Citric acid monohydrate as a release-modifying agent in melt extruded matrix tablets.
    Schilling SU; Bruce CD; Shah NH; Malick AW; McGinity JW
    Int J Pharm; 2008 Sep; 361(1-2):158-68. PubMed ID: 18582547
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Method to recover a lipophilic drug from hydroxypropyl methylcellulose matrix tablets.
    Williams RO; Sykora MA; Mahaguna V
    AAPS PharmSciTech; 2001 Jun; 2(2):E8. PubMed ID: 14727883
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Effects of drug solubility on the release kinetics of water soluble and insoluble drugs from HPMC based matrix formulations.
    Chakraborty S; Khandai M; Sharma A; Patra ChN; Patro VJ; Sen KK
    Acta Pharm; 2009 Sep; 59(3):313-23. PubMed ID: 19819827
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Influence of dissolution medium agitation on release profiles of sustained-release tablets.
    Paulo ; Sousa Lobo JM
    Drug Dev Ind Pharm; 2001 Sep; 27(8):811-7. PubMed ID: 11699832
    [TBL] [Abstract][Full Text] [Related]  

  • 45. A predictive model for the release of slightly water-soluble drugs from HPMC matrices.
    Fu XC; Wang GP; Wang YH; Liang WQ
    Pharmazie; 2004 Aug; 59(8):624-6. PubMed ID: 15378852
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Mechanistic Approach to Understanding the Influence of USP Apparatus I and II on Dissolution Kinetics of Tablets with Different Operating Release Mechanisms.
    Lu Z; Fassihi R
    AAPS PharmSciTech; 2017 Feb; 18(2):462-472. PubMed ID: 27106916
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Study the effect of formulation variables on drug release from hydrophilic matrix tablets of milnacipran and prediction of in-vivo plasma profile.
    Singhvi G; Shah A; Yadav N; Saha RN
    Pharm Dev Technol; 2014 Sep; 19(6):708-16. PubMed ID: 23931031
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Designing HPMC matrices with improved resistance to dissolved sugar.
    Williams HD; Ward R; Culy A; Hardy IJ; Melia CD
    Int J Pharm; 2010 Nov; 401(1-2):51-9. PubMed ID: 20858538
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Gum Ghatti--a pharmaceutical excipient: development, evaluation and optimization of sustained release mucoadhesive matrix tablets of domperidone.
    Gurpreetarora ; Malik K; Rana V; Singh I
    Acta Pol Pharm; 2012; 69(4):725-37. PubMed ID: 22876617
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The butterfly effect: a physical phenomenon of hypromellose matrices during dissolution and the factors affecting its occurrence.
    Cahyadi C; Chan LW; Colombo P; Heng PW
    Int J Pharm; 2011 Mar; 406(1-2):31-40. PubMed ID: 21187134
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Preparation and evaluation of novel metronidazole sustained release and floating matrix tablets.
    Asnaashari S; Khoei NS; Zarrintan MH; Adibkia K; Javadzadeh Y
    Pharm Dev Technol; 2011 Aug; 16(4):400-7. PubMed ID: 20429828
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Compaction properties, drug release kinetics and fronts movement studies from matrices combining mixtures of swellable and inert polymers. II. Effect of HPMC with different degrees of methoxy/hydroxypropyl substitution.
    Escudero JJ; Ferrero C; Jiménez-Castellanos MR
    Int J Pharm; 2010 Mar; 387(1-2):56-64. PubMed ID: 19969052
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Development and release mechanism of diltiazem HCl prolonged release matrix tablets.
    Boyapally H; Nukala RK; Douroumis D
    Drug Deliv; 2009 Feb; 16(2):67-74. PubMed ID: 19267297
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Production of extended release mini-tablets using directly compressible grades of HPMC.
    Mohamed FA; Roberts M; Seton L; Ford JL; Levina M; Rajabi-Siahboomi AR
    Drug Dev Ind Pharm; 2013 Nov; 39(11):1690-7. PubMed ID: 23078551
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Photostability of extended-release matrix formulations.
    Maggi L; Ochoa Machiste E; Fasani E; Albini A; Segale L; Conte U
    Eur J Pharm Biopharm; 2003 Jan; 55(1):99-105. PubMed ID: 12551710
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Release of theophylline and carbamazepine from matrix tablets--consequences of HPMC chemical heterogeneity.
    Viridén A; Abrahmsén-Alami S; Wittgren B; Larsson A
    Eur J Pharm Biopharm; 2011 Aug; 78(3):470-9. PubMed ID: 21316446
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Factors affecting drug release from hydroxypropyl methylcellulose matrix systems in the light of classical and percolation theories.
    Caraballo I
    Expert Opin Drug Deliv; 2010 Nov; 7(11):1291-301. PubMed ID: 20977292
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Effect of source variation on drug release from HPMC tablets: linear regression modeling for prediction of drug release.
    Piriyaprasarth S; Sriamornsak P
    Int J Pharm; 2011 Jun; 411(1-2):36-42. PubMed ID: 21420475
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The effect of pore-formers and plasticizers on the release kinetic of diltiazem hydrochloride from the controlled porosity osmotic pumps.
    Shokri J; H Zarrintan M; Ghanbarzadeh S; Arash Z; Farahani A; Adibkia K
    Drug Res (Stuttg); 2013 Aug; 63(8):414-9. PubMed ID: 23599037
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Effect of various surfactants and their concentration on controlled release of captopril from polymeric matrices.
    Nokhodchi A; Hassan-Zadeh D; Monajjem-Zadeh F; Taghi-Zadeh N
    Acta Pharm; 2008 Jun; 58(2):151-62. PubMed ID: 18515225
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.